Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient
Clinical and Molecular Hepatology
;
: 85-88, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-64639
ABSTRACT
Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib. Tumor lysis syndrome induced by low-dose steroid appears to be very unusual in HCC. We report a patient with hepatitis-C-related liver cirrhosis and HCC in whom tumor lysis syndrome occurred due to low-dose steroid (10 mg of prednisolone). The patient was a 90-year-old male who presented at the emergency room of our hospital with general weakness and poor oral intake. He had started to take prednisolone to treat adrenal insufficiency 2 days previously. Laboratory results revealed hyperuricemia, hyperphosphatemia, and increased creatinine. These abnormalities fulfilled the criteria in the Cairo-Bishop definition of tumor lysis syndrome. Although the patient received adequate hydration, severe metabolic acidosis and acute kidney injury progressed unabated. He finally developed multiple organ failure, and died 3 days after admission. This was a case of tumor lysis syndrome caused by administration of low-dose steroid in a patient with HCC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos de Fenilureia
/
Esteroides
/
Síndrome de Lise Tumoral
/
Tomografia Computadorizada por Raios X
/
Quimioembolização Terapêutica
/
Niacinamida
/
Carcinoma Hepatocelular
/
Creatinina
/
Injúria Renal Aguda
/
Neoplasias Hepáticas
Limite:
Idoso
/
Aged80
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clinical and Molecular Hepatology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS